Scientists/Clinicians
Introduction
The aim of the research funded by the Cancer Vaccine Institute (CVI) is to provide an environment where putative cancer vaccines can be tested, both in the laboratory and, where appropriate in the clinic.
The Research is undertaken by Professor Angus Dalgleish Bsc (Hons) MBBS MD FRACPath FRACP FRCP FMed Sci and his team at St George's University of London and at other centres around the country. A Scientific Board, made up of a panel of scientists and clinicians is responsible for independently assessing and prioritising research projects.
The CVI was originally set up to assess the melanoma vaccine of Dr Donald Morton at the John Wayne Cancer Institute. A similar approach was used to screen putative vaccines for prostate cancer which were subsequently developed by Onyvax Limited. The CVI now funds a portfolio of pre-clinical research aimed at manipulating the immune system through drug/cell interactions or through manipulation of dendritic cells in vitro. A biomarker discovery program has been funded to look for predictive markers of response using sera from patients treated with a dendritic cell vaccine.
Recently a studentship was funded at Kings College London to study immunotherapy in AML. This is the first such "externally" funded position but more may become available in the future. Please return to this website for updates on ongoing work and potential funding opportunities.
We rely solely on voluntary contributions to fund our Research costs which include laboratory and out-patient facilities, consumables and salaries of the research team.
